

Index

Page numbers in boldface refer to tables; page numbers in *italic* refer to figures.

Abbreviations used in subheadings:

CSF = cerebrospinal fluid
 MRI = magnetic resonance imaging
 PND = perioperative neurocognitive disorders
 POCD = postoperative cognitive dysfunction

- ISD rule, incidence analysis 130
- abdominal surgery 63; *see also* bariatric surgery
- acetylcholine *see* cholinergic system
- Activities of Daily Living (ADL) scale 174–175
- acute kidney injury (AKI), systemic inflammation 104–105
- acute-phase inflammatory response 101–102; *see also* inflammation
- age factors in PND 14–15, 26–27, 115–117
 animal models 64–73
 emergence delirium 1–2
- aging populations
 informed consent 179, 187
 preoperative testing 167
- agitation, emergence delirium 2
- alarmins 63; *see also* high-mobility group box 1 (HMGB1)
- Alzheimer's disease (AD) 49–50
 cholinergic system 93
 imaging 152, 155–156, 155–157
 inflammatory response in relation to surgery 109–110
 medical decision-making capacity 182
 PND mitigation 191
 neurotoxicity of anesthetics 82, 85–86
see also dementia
- Alzheimer's Disease Neuroimaging Initiative (ADNI) 51
- American Society of Anesthesiologists, disclosure of information recommendations 185–186
- AMPA (α amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptors 93, 95
- amyloid-beta plaques
 biomarkers 138–144, 145–146, 155–156
 inflammatory response in relation to surgery 109–110
 neurotoxicity of anesthetics 82–83, 83, 86
- amyloid hypothesis, Alzheimer's disease 50, 50
- anesthetic agent/administration route 27, 29
 animal models 62, 65–72
 emergence delirium 1–2, 7
 PND mitigation 191–192
 postsurgical dementia 54–57
 postoperative delirium 15–16
 regional vs. general anesthesia 190–193
see also depth of anesthesia; neurotoxicity of anesthetics; stress response to anesthesia; total intravenous anesthesia; volatile anesthetics and *see specific anesthetics*
- animal models x, 61, 65–72
 anesthetic agent/administration route 62, 65–72
 assessment of cognitive function 73–76
 control and monitoring of anesthesia 62
- dementia 52
 environmental enrichment 28
 future research needs 76–77
 and informed consent in humans 186
 neuroprotective effects of anesthetic agents 87
 neurotoxicity of anesthetics 82–85
 preexisting vulnerabilities 64–73
 receptor-based mechanisms 94–95
 scaling up for translational relevance 62–63
 stress response to anesthesia 63
 surgery type 63, 63, 65–72
 systemic inflammation 63–64
 volatile anesthetics 191
- anticholinergic medication 16, 57, 96
- anticholinesterase therapy, PND mitigation 194
- anti-inflammatory medication, PND mitigation 193–194; *see also* statins
- antipsychotic medication 18–20
- aortic valve replacement, postoperative cognitive improvement 35
- APOE (apolipoprotein) gene, biomarkers 138–144, 146–147
- apoptosis, due to inflammation 106–107
- assessment of cognitive function *see* cognitive testing

- atropine 94
 attentional response, animal
 cognitive assessment 75–76
 attitudinal factors *see* patient-related factors
- barbiturates, neuroprotective effects 86–87
- bariatric surgery, postoperative cognitive improvement 35–36
- Barnes maze, animal cognitive assessment 75
- baseline levels
 age factors 64
 animal models 76–77
 cognitive reserve 28
 cognitive testing 123, 126
 coronary artery disease patients 28
 delirium risk factors 14, 17
 neuroimaging 156, 159–163, 161
 POCD 25
 postoperative cognitive improvement 35
 postsurgical dementia 53
- behavioral change,
 biopsychosocial model of health 37–38
- benzodiazepines
 emergence delirium 3
 neuroprotective effects 88
 pharmacological management guidelines 18–20
 POCD risks to patients 192–193
 postsurgical dementia 57
- best practice xi, 18; *see also* mitigation strategies
- beta-amyloid plaques *see* amyloid-beta plaques
- biological factors
 biopsychosocial model of health 37–38
 postoperative cognitive improvement 38–39
- biomarkers of PND x, 39, 134, 136–137, 147–148
 blood sources 135–145
 classification of types 134–135
 CSF 136–137, 145–146
 dementia 50–51, 53–55
 DNA sources 136–137, 146–147
 intraoperative monitoring 136–137, 147
 listing of specific biomarkers 138–144
 neurotoxicity of anesthetics 86, 86
 urine sources 134–135, 136–137
 see also neuroimaging biomarkers
- biopsychosocial model of health 37–40
- bispectral index (BIS)
 biomarkers 147
 emergence delirium 7
 postoperative delirium 16
- blood-brain barrier (BBB) x, 30
 anticholinergic medication 96
 delirium 13
 mechanisms of cognitive dysfunction 192–193
 systemic inflammation 105–106
- blood loss, and postoperative delirium 16
- blood oxygen level-dependent (BOLD) functional imaging 153, 153–163
- blood pressure values, and postoperative delirium 16
- blood testing, biomarkers 135–145
- brain perfusion, perioperative monitoring 194
- brain states during anaesthesia 148; *see also* structural hypothesis
- burst suppression EEG patterns
 biomarkers 147
 structural hypothesis of emergence delirium 7
- C-reactive protein, biomarkers 138–144, 145
- capacity, cognitive, role in informed consent 179, 182–185
- cardiac surgery, PND 27–29, 92
 white matter imaging 159–164, 159–160
- cardiovascular disease
 risk factors for PND x
 systemic inflammation 102–104
- caregiver support,
 postoperative cognitive improvement 41
- central nervous system (CNS)
 dysfunction, systemic inflammation 105–106
- cerebrospinal fluid (CSF),
 biomarkers 86, 136–144, 145–146
- cerebrovascular disease, risk factors for PND 27
- children, systematic study of emergence delirium 1–2
- cholinergic anti-inflammatory pathway 96, 116–117
- cholinergic medication, PND mitigation 193–194
- cholinergic system 30
 delirium 12–13, 16
 mechanisms of POCD 93–97, 193–194
- chronic inflammation *see* inflammation
- clinical nomenclature *see* definitions/clinical nomenclature
- cognitive capacity, role in informed consent 179, 182–185
- cognitive domains, assessment 124, 126, 127, 132
- cognitive function
 and PND 39–40
 postoperative delirium 11
 see also mild cognitive impairment
- cognitive phenotypes of dementia 52
- cognitive reserve, PND 27–28
- cognitive testing 24, 123–124, 132
 animal models 73–76
 appropriate assessment instruments 126–127
 assumptions/testing issues 126–129
 baseline levels 123, 126
 controls, research 125
 definitions 123, 129
 group vs. individual analysis 129–130
 inappropriate assessment instruments 124

- incidence analysis 130–132, 131
 postoperative cognitive improvement 39–40
 postoperative delirium 17
 preoperative testing of vulnerable subgroups 168–170
 repeat testing issues/practice effects 125–128
 schematic representation of POCD 128
 standard methodology 124–125
 test batteries 123–125
see also screening tools
 combined z-scores, incidence analysis 131–132
 communication of POCD risks to patients 185–187; *see also* informed consent for anesthetics
 comorbidities 115
 age factors 115–117
 animal models 73
 infection 118
 metabolic syndrome/disorders 117
 risk factors for PND 14–15
see also inflammation
 competence, medical decision-making capacity 182–185; *see also* informed consent for anesthetics
 consciousness, structural hypothesis of 3–7
 Consortium to Establish a Registry for Alzheimer's Disease (CERAD), cognitive testing 127
 contextual fear conditioning (CFC), animal cognitive assessment 74–75
 Controlled Oral Word Association Test (COWAT) 127
 controls, research
 cognitive testing 125
 dementia studies 56
 coronary artery bypass grafting (CABG) 28, 35
 coronary artery disease (CAD) 28
 corticosteroids, PND mitigation 193–194
 cortisol levels 13, 30
 CRP (C-reactive protein), biomarkers 138–144, 145
 CSF *see* cerebrospinal fluid
 damage-associated molecular patterns (DAMPs)
 aging patients 116
 biomarkers of PND 135–145
 metabolic syndrome/disorders 117
 systemic inflammation 105
 definitions/clinical nomenclature
 cognitive testing 123, 129
 emergence delirium 1, 3
 mild cognitive impairment, preoperative 180
 neurocognitive disorder 25
 PND ix–x, 25, 85, 123, 129
 POCD 25, 85, 123, 129, 181
 postoperative cognitive improvement 36–42
 delayed neurocognitive recovery (dNCR)
 biomarkers of PND 135
 definitions 25
 informed consent 181
 delirium 1, 11, 20–21
 diagnosis 17
 differential diagnosis 17
 etiology 13–16, 14
 incidence 11–12
 pathophysiology 12–13, 12
 pharmacological management 18–20
 phenotypes of disordered cognition 52
 postoperative factors 16
 prevention 18–19
 treatment/management 14–20, 18–20
see also emergence delirium
 dementia, postsurgical 29, 48, 57
 Alzheimer's disease 49–50
 biomarkers 51, 53–55
 date of onset/progression of disease 50
 establishing relationship with surgery 50–51
 future research needs 52–57, 54–57
 nature of 48–49
 phenotypes of disordered cognition 52
 and postoperative delirium 11
 prevention 57
 retrospective, case-control studies 51
 seminal studies 24, 48
 in vitro and animal data 52
 depression 115
 preoperative testing 170–171
 depth of anesthesia 29
 emergence delirium 7
 PND mitigation 192
 postoperative delirium 16
 desflurane
 neuroprotective effects 87
 neurotoxicity 84, 86
 POCD risks to patients 191
 dexamethasone, PND mitigation 193
 dexmedetomidine, postoperative delirium 16
 diabetes
 PND mitigation 194–195
 risk factors for PND x, 27
 diagnostic instruments *see* cognitive testing
 differential diagnosis, postoperative delirium 17
 diffusion-weighted imaging (DWI), white matter hyperdensities 159–160, 160
 Digit Symbol Substitution Test 127
 DNA biomarkers 136–137, 146–147; *see also* genotyping
 donepezil 94, 194
 dopaminergic system 13, 30
 dose-response curves, induction of vs. emergence from anesthesia 4, 5
 doxapram, agitation 2–3
 early-onset Alzheimer's disease (EOAD) 49
 Edmonton Frail Scale 172–173
 educational level, and PND 27
 8-isoprostane:creatinine (U8-isoPG:Cr) biomarkers 134–135, 138–144

- electroencephalography (EEG)
 147
 biomarkers 147
 perioperative monitoring 194
 structural hypothesis of
 emergence delirium 7
 emergence delirium 1–2, 7
 incidence 1–3, 7
 literature review 2–3
 phenotypes of disordered
 cognition 52
 structural hypothesis 3–7, 4
 end-product biomarkers of
 PND 134–135, 134
 endothelial cell biomarker 145
 environmental enrichment,
 animal studies 28, 83
 EOAD (early-onset Alzheimer's
 disease) 49
 epidemiology *see* incidence and
 prevalence
 epilepsy surgery, postoperative
 cognitive improvement
 34–35
 etiologic biomarkers 134–135,
 134
 executive function 15, 17, 25
 assessment in animals
 75–76
 postoperative cognitive
 improvement 35
 exercise program interventions
 28, 194–195
 extrinsic frailty *see* social
 vulnerability
 fear conditioning, animal
 cognitive assessment 74–75
 fibrinopeptide A biomarkers
 138–144, 145
 flortaucipir biomarkers
 155–156
 fluid attenuated inversion
 recovery sequencing
 (FLAIR), white matter
 hyperdensities 159–164,
 159–164
 FRAIL Questionnaire 172–173
 frailty
 preoperative testing 171–173
 risk factors for PND 15, 27
 Fried Frailty Phenotype 172
 functional connectivity
 magnetic resonance
 (fcMRI) 153–154, 154,
 156, 160–163, 162
 functional magnetic resonance
 imaging (fMRI) 153–163,
 153–163
 future research needs
 animal models 76–77
 POCD mitigation 195
 postsurgical dementia 52–57,
 54–57
 GABA (gamma-aminobutyric
 acid) receptors 93, 97,
 191–192
 GABAergic anesthetics,
 neuroprotective effects 85,
 88
 general vs. regional anesthesia,
 POCD risks 190–191
 genotyping, early-onset
 Alzheimer's disease 50; *see*
also DNA biomarkers
 glucose metabolism,
 postoperative cognitive
 improvement 38
 glutamate receptors 92–95
 glycogen synthase kinase-3
 (GSK3),
 neuroinflammation 108
 gray matter integrity
 dementia 51
 postoperative cognitive
 improvement 38
 Grooved Pegboard Test 127
 haloperidol, POCD risks
 192–193
 health, biopsychosocial model
 37–38; *see also*
 postoperative cognitive
 improvement
 high-mobility group box 1
 (HMGB1) biomarkers
 138–144, 145
 hippocampal volume
 biomarkers 156, 156–157
 hypoactive delirium 20–21
 differential diagnosis 17
 hypoactive emergence 2
 hysteresis, structural
 hypothesis 5
 iatrogenic factors
 postoperative delirium 16
 risk factors for PND 14–15
see also anesthetic agent/
 administration route
 imaging *see* neuroimaging
 immune system, stress response
 to anesthesia 63
 incidence analysis, cognitive
 testing 130–132, 131
 incidence and prevalence
 aging patients 115
 emergence delirium 1–3, 7
 mild cognitive impairment,
 preoperative 180
 PND 25–26, 26
 POCD 180–181
 postoperative delirium 11–12
 independent activities of daily
 living (IADL)
 questionnaire 174–175
 infection, comorbidities 118
 inflammation 101, 112, 115
 aging patients 115–117
 animal models 63–64
 biomarkers 145
 due to inflammation
 106–108, 107
 delirium 13
 infection 118
 metabolic syndrome/
 disorders 117
 mild cognitive impairment,
 preoperative 180
 multiorgan dysfunction
 102–106
 neuroimaging 157–165
 novel therapeutics 110–112
 PND 28, 30, 108–109
 POCD 95
 postoperative cognitive
 improvement 39
 stress response to anesthesia
 63
 systemic inflammation
 102–103
 trauma caused by surgery
 101–102
see also comorbidities;
 systemic inflammatory
 response syndrome
 inflammatory reflex
 96
 information provision to
 patients 185–187
 informed consent for
 anesthetics x, 179, 187
 and cognition 182
 cognitive capacity 182–185
 dementia studies 53, 55
 disclosure of information
 185–187

- mild cognitive impairment, preoperative 180
 neurotoxicity of anesthetics 85
 postoperative cognitive state 180–181, 181
 inhalational anesthetics *see* volatile anesthetics
 injectable anesthetics *see* total intravenous anesthesia
 innate immune system, stress response 63
 International Study of Postoperative Cognitive Dysfunction (ISPOCD) 25, 115
 intraoperative factors, postoperative delirium 15–16
 intraoperative monitoring *see* monitoring of anesthesia
 intravenous anesthetics *see* total intravenous anesthesia
 isoflurane
 neuroprotective effects 87
 neurotoxicity 82–83, 86
 POCD risks to patients 191
 ketamine, neurotoxicity 85
 kidney transplant
 patients, postoperative cognitive improvement 35–36
 late-onset Alzheimer's disease (LOAD) 49
 Levinthal's paradox, protein folding 4, 5–6
 lidocaine, PND mitigation 193
 lifestyle habits, postoperative cognitive improvement 40–41
 lipopolysaccharide (LPS), animal models 64, 73, 96
 lipoxins, chronic inflammation 116
 literature review, emergence delirium 2–3
 LOAD (late-onset Alzheimer's disease) 49
 lung impairment, systemic inflammation 104
 macrophages 96, 101, 103, 105–106, 192–193; *see also* inflammatory reflex
 magnetic resonance imaging (MRI) 152–154, 153–163
 mazes, animal cognitive assessment 75; *see also* Barnes maze; Morris water maze
 MCI *see* mild cognitive impairment
 medical decision-making capacity 183; *see also* informed consent for anesthetics
 melatonin, delirium 13
 memory, effects of anesthetics 25, 35
 metabolic syndrome/disorders 13
 animal models 73
 comorbidities 117
 see also diabetes
 microglia 105, 108–110, 116
 mild cognitive impairment (MCI) 29
 animal models 73
 informed consent 180
 nature of 48–49
 preoperative testing 167–170
 risk factors for PND x, 15
 seminal studies 48
 Mini-Cog test 168–169
 Mini Mental State Examination (MMSE) 127, 168, 169–170
 mitigation strategies 190, 195
 anesthetic agent 191–192
 anti-inflammatory medications 193–194
 delirium 18–19
 dementia 57
 depth of anesthesia 192
 multidisciplinary medical teams 15
 nutritional approaches 116, 194–195
 perioperative monitoring 194
 prehabilitation 194–195
 regional vs. general anesthesia 190–191
 sedatives/psychotropics 192–193
 surgery type 192–193
 see also rehabilitation programs
 mitochondrial dysfunction, and delirium 13
 monitoring of anesthesia 136–137, 147
 animal models 62
 PND mitigation 194
 monocytes 101, 105, 192–193
 Montreal Cognitive Assessment (MoCA) 127
 Morris water maze 74
 motor function, animal assessment 76
 MRI *see* magnetic resonance imaging
 multiorgan dysfunction 102–106
 multidisciplinary care teams 15
 N-methyl-D-aspartate (NMDA) receptors 92–95
 N-methyl-D-aspartate (NMDA) antagonists, neurotoxicity 84–85
 nasal surgery, emergence delirium 2
 necrosis, due to inflammation 106–107
 neuroanatomical factors, postoperative cognitive improvement 38
 neurocognitive disorder (NCD)
 definitions 25
 outcomes 26
 risk factors 27–29
 neurofibrillary tangles (NFT), neurotoxicity of anesthetics 85
 neurofilament light, biomarkers 137
 neurogenesis, due to inflammation 107–108
 neuroimaging 152, 161–162, 163
 Alzheimer's disease 152, 155–156, 155–157
 functional connectivity MRI 160–163, 162
 inflammation 157–165, 157–159
 magnetic resonance imaging 152–154, 153–163

- neuroimaging (cont.)
 positron emission tomography 154–155
 post-cardiac surgery, white matter hyperdensities 159–164, 159–160
- neuroimaging biomarkers 136–137, 163
 amyloid-beta plaques 155–156
 flortaucipir 155–156
 hippocampal volume/function 156, 156–157
 Pittsburgh Compound B 155, 155
 translocator protein 155, 157–165, 157–159
- neuroinflammation *see* inflammation
- neuronal death, due to inflammation 106–107
- neuropathy, preexisting *see* mild cognitive impairment
- neuroprotective effects, anesthetics 82, 86–88, 87, 94–95; *see also* postoperative cognitive improvement
- neuropsychological domains, cognitive testing 124, 126, 127, 132
- neurotoxicity of anesthetics 82, 87–88
 clinical studies 85–86
 neuroprotective effects 82, 86–88, 87
 preclinical studies 82–85
- neurotransmitters 12–13, 30; *see also* receptor-based mechanisms
- nicotine 94, 111–112
- nitric oxide (NO)
 biomarkers 138–144, 145
 systemic inflammation 102–104
- nitrous oxide (N₂O), neurotoxicity of anesthetics 84–85
- nomenclature *see* definitions/clinical nomenclature
- NSAIDs (nonsteroidal anti-inflammatory drugs), PND mitigation 193–194
- nutritional approaches, PND mitigation 116, 194–195
- operation type *see* surgery type
- opioids, risk factors for PND 3, 15
- orthopedic surgery
 animal models 63
 postoperative cognitive improvement 36
- oxygenation/perfusion, perioperative monitoring 194
- pain, untreated
 postoperative cognitive improvement 39
 postoperative delirium 16
 risk factors for PND 3, 15, 27
- parecoxib, PND mitigation 193
- Parkinson's disease, medical decision-making capacity 184
- pathophysiologic biomarkers of PND 134–135, 134
- patient-related factors 27–28, 27–28
 postoperative cognitive improvement 40
 postsurgical dementia 54–57
- pediatrics, systematic study of emergence delirium 1–2
- perioperative neurocognitive disorders, general assumptions underlying testing 126–129
 definitions ix–x, 25, 85, 123, 129
 inflammatory response in relation to surgery 108–109
 neuroimaging 159–163, 159–164
 prevention *see* mitigation strategies
 risk factors 36, 37
 as syndrome or disease 148
see also postoperative cognitive dysfunction and other specific conditions
- personality, and postoperative cognitive improvement 40
- PET (positron emission tomography) 154–155
- phenotypes of dementia 52
- Pittsburgh Compound B (PiB) biomarkers 155, 155
- PND *see* perioperative neurocognitive disorders
- POCD *see* postoperative cognitive dysfunction
- POCI *see* postoperative cognitive improvement
- polyunsaturated fatty acids *see* nutritional approaches
- positron emission tomography (PET) 154–155
- postconditioning 87
- postoperative cognitive dysfunction, general ix, 24, 30
 assumptions underlying testing 126–129
 biopsychosocial model of health 37–38
 cognitive testing 123–124
 definitions 25, 85, 123, 129, 181
 follow-up studies 181
 incidence 26
 informed consent 180–181, 185–187
 outcomes 26
 pathophysiology 30
 phenotypes of disordered cognition 52
 prevalence 25–26
 risk factors 27–29, 37
 schematic representation 128
see also perioperative neurocognitive disorders and other specific conditions
- postoperative cognitive improvement ix, 34, 41
 biological factors 38–39
 biopsychosocial model of health 37–38
 definitions/clinical nomenclature 36–42
 epilepsy surgery 34–35
 psychosocial factors 39–40
 receptor-based mechanisms 94–95
 social factors 40–41
- postoperative delirium *see* delirium
- postsurgical dementia *see* dementia
- precipitating factors, postoperative delirium 13–15, 14; *see also* risk factors; vulnerability to PND

- preclinical studies x
 neurotoxicity of anesthetics 82–85
- predisposing factors,
 postoperative delirium 13–15, 14; *see also* risk factors; vulnerability to PND
- preexisting cognitive impairment *see* mild cognitive impairment
- prehabilitation
 PND mitigation 194–195
 postoperative cognitive improvement 36, 40–41
- preoperative testing *see* vulnerability to PND
- prevalence *see* incidence and prevalence
- prevention of PND *see* mitigation strategies
- pro-inflammatory cytokines 116
- biomarkers of PND 145
 inflammatory response in relation to surgery 103
 metabolic syndrome/ disorders 117
 POCD risks to patients 192–193
 systemic inflammation 105–106
see also inflammation
- propofol
 neuroprotective effects 87, 88
 neurotoxicity 85
 POCD risks to patients 191
 PND mitigation 193–194
- protein folding example,
 structural hypothesis of emergence delirium 4, 5–6
- proteomics, biomarkers of PND 145
- psychological factors
 biopsychosocial model of health 37–38
 postoperative cognitive improvement 40
- psychosocial factors,
 postoperative cognitive improvement 39–40
- psychotropic drugs, POCD risks to patients 192–193
- PUFAs (polyunsaturated fatty acids) *see* nutritional approaches
- pulmonary impairment,
 systemic inflammation 104
- rat models *see* animal models
- receptor-based mechanisms,
 POCD 92, 97, 98
 cholinergic system 93–97
 GABA receptors 93, 97
 glutamate receptors 92–95
 other receptor signaling systems 97
- regional vs. general anesthesia,
 POCD risk 190–193
- rehabilitation programs 19, 36;
see also mitigation strategies
- reliable change index (RCI) 130–131, 131
- renal dysfunction, systemic inflammation 104–105
- renin-angiotensin system (RAS) 97
- resolvins, chronic inflammation 116
- respiratory dysfunction,
 systemic inflammation 104
- risk factors 27–29, 37
 biomarkers of PND 134–135, 134
 disclosure of POCD risks to patients 185–187
 postoperative delirium x, 13–15, 14
 preoperative testing 167, 170
see also vulnerability to PND
- rivastigmine 94
- rodent models *see* animal models
- S-100 β protein biomarkers 135–145
- salivary biomarkers 136–137
- scopolamine 94
- screening tools
 depression 171
 frailty 172
 mild cognitive impairment, preexisting 169–170
 social vulnerability 174–175
see also cognitive testing
- sedatives, POCD risks 190, 192–193; *see also* benzodiazepines
- Semantic Fluency Test 127
- Senegenin natural medicine, neuroprotective effects 95
- sepsis, animal models 63–64
- serum anticholinergic activity (SAA) 95–96; *see also* cholinergic system
- sevoflurane
 neuroprotective effects 87
 neurotoxicity 83
 POCD risks 191
- SHARE Frailty Instrument 172
- sickness behavior
 animal models 64
 systemic inflammation 193
- single nucleotide polymorphisms (SNPs) 146–147
- SIRS *see* systemic inflammatory response syndrome
- 6-sulfatoxymelatonin (6-SMT) biomarkers 134–135
- social factors
 biopsychosocial model of health 37–38
 postoperative cognitive improvement 39–41
- social vulnerability,
 preoperative testing 173–175
- state transitions, structural hypothesis of emergence delirium 6
- statins, PND mitigation 38, 110–111
- steroids, PND mitigation 193–194
- STOP DELIRIUM mnemonic 14–20, 18–20
- stress response to anesthesia 63–73, 65–72
- Stroop test 127
- structural hypothesis,
 emergence delirium 3–7, 4
- subjective reports, PND 24
- surgery type 27–28, 192–193
 animal models 63, 65–72
 emergence delirium 1–2
 postsurgical dementia 54–57
 postoperative delirium 15–16
see also trauma caused by surgery
- synaptic impairment, due to inflammation 106

- syndrome, PND as 148
 systemic inflammatory response syndrome (SIRS)
 animal models 63–64
 mild cognitive impairment 180
 multiorgan dysfunction 102–106
 pathogenesis 103
 surgery-induced 102, 192–193
 see also inflammation
 tau-based biomarkers 50, 86, 137, 145–146, 155; *see also* amyloid-beta plaques
 test batteries, cognitive testing 123–125
 thiopental, neuroprotective effects 86–87
 tissue (brain) perfusion, perioperative monitoring 194
 TNF (tumor necrosis factor) alpha, inflammatory response in relation to surgery 103, 105–106
 total intravenous anesthesia (TIVA)
 emergence delirium 3
 neuroprotective effects 86–87
 neurotoxicity of anesthetics 85
 PND mitigation 191, 193–194
 see also specific agents
 Trail-Making Test 127
 transgenic mouse models 73
 translocator protein (TSPO)
 biomarkers 155, 157–165, 157–159
 trauma caused by surgery 101–102
 20% rule, incidence analysis 130
 urine testing, biomarkers 134–135, 136–137
 vagal hypotonia 116
 volatile anesthetics 147
 emergence delirium 3
 neuroprotective effects of anesthetic agents 87
 PND mitigation 191–192
 see also specific agents
 vulnerability to PND 167, 175
 animal models 64–73, 65–72
 depression 170–171
 frailty 171–173
 mild cognitive impairment, preexisting 167–170
 social vulnerability 173–175
 see also risk factors
 weight loss, post-operative cognitive improvement 36
 white matter integrity
 post cardiac surgery, imaging 159–164, 159–160
 postoperative cognitive improvement 38
 xenon, novel therapeutics for PND 111